Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd (AKUMS) last traded at ₹745, a market capitalisation of ₹11,729 crore, on a P/E of 38.4. Over the past 52 weeks the stock has ranged between ₹409 and ₹783. Akums Drugs and Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,167 crore and net profit of ₹101 crore. The next scheduled event is an analyst meet on 2 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Akums Drugs and Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Akums Drugs and Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,167 cr, up 14.0% from ₹1,024 cr a year earlier. Net profit was ₹101 cr, up 55.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating profit | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other income | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net profit | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS (₹) | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Akums Drugs and Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Operating profit | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 9% | -2.4% | 8% | 3.0% | 11% | 12% | 13% |
| Net profit | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS (₹) | 943.49 | -35.30 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
TTM is the trailing twelve months to the most recent quarter.
Akums Drugs and Pharmaceuticals Ltd growth and returns
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 6%
- TTM
- 9%
- 10 Years
- 16%
- 5 Years
- 16%
- 3 Years
- 29%
- TTM
- -7%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 61%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 10%
- Last Year
- 8%
Akums Drugs and Pharmaceuticals Ltd shareholding pattern
Promoters held 75.26% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.91% and DIIs 13.44%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FIIs | 7.34% | 6.36% | 5.77% | 4.24% | 2.27% | 1.14% | 1.38% | 1.91% |
| DIIs | 7.53% | 6.99% | 7.39% | 8.85% | 9.28% | 14.41% | 14.36% | 13.44% |
| Public | 7.14% | 8.64% | 8.84% | 8.92% | 10.46% | 6.45% | 6.29% | 6.67% |
| No. of shareholders | 57,531 | 68,410 | 69,366 | 69,424 | 75,365 | 76,869 | 72,589 | 70,289 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Akums Drugs and Pharmaceuticals Ltd events
The next scheduled event is an analyst meet on 2 Sept 2026.
- Analyst meetParticipation in Ashwamedh – Elara India Dialogue 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Akums Drugs and Pharmaceuticals Ltd corporate filings
- Intimation of Schedule of the Investors/Analysts MeetCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding a scheduled…
Read the full analysis - Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited has issued a formal update regarding the schedule…
Read the full analysis - Intimation of Schedule of the Investors/Analysts MeetCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding a scheduled…
Read the full analysis - Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27Company Updatehigh impact
Cruxal's analysis: Akums Drugs & Pharmaceuticals Limited delivered a strong Q1 FY27 performance, with…
Read the full analysis - Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has announced an intimation for an upcoming investor…
Read the full analysis - Link of audio recording of Investors/Analysts Conference CallCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has filed the audio recording link for its recent…
Read the full analysis - Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has released a standard newspaper publication as part…
Read the full analysis - Monitoring Agency Report for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has filed its Monitoring Agency Report for the…
Read the full analysis - Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited delivered a robust performance for Q1 FY27…
Read the full analysis - Press ReleaseCompany Updatelow impact
Cruxal's analysis: The company has filed a press release on August 8, 2026. The disclosure is a routine…
Read the full analysis - Un-audited Financial Results for the Quarter ended 30th June, 2026Board Meetinghigh impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited reported strong Q1 FY27 consolidated financial…
Read the full analysis - Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY27Company Updatelow impact
Cruxal's analysis: Akums Drugs & Pharmaceuticals Limited has formally announced an investor and analyst…
Read the full analysis - Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve the un-audited ....Board Meetinglow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited has formally intimated the stock exchanges…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Akums Drugs and Pharmaceuticals Ltd
Cruxal reads every Akums Drugs and Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.